Aprotinin in adults at high risk of major blood loss during isolated CABG with cardiopulmonary bypass: a profile of its use in the EU
- 34 Downloads
Prophylactic treatment with aprotinin, a haemostatic antifibrinolytic agent, is indicated to reduce blood loss and blood transfusion in adults with a high risk of major bleeding undergoing primary or repeat isolated coronary artery bypass graft (CABG) with cardiopulmonary bypass. Overall, aprotinin was consistently more effective than tranexamic acid, ε-aminocaproic acid, desmopressin and placebo in reducing massive blood loss, the need for transfusions of blood products, and the need for reoperation due to diffuse bleeding in trials in this patient population, and was generally well-tolerated. The approval of aprotinin in the EU was reinstated by the European Medicines Agency (EMA) in 2012, following subsequent analysis of the clinical data that led to its suspension in 2007. The EMA analysis concluded that the reduction in massive bleeding provided by aprotinin in patients undergoing isolated CABG is clinically relevant, as it reduces complications, the need for blood product transfusions and the length of hospital stay, without increasing mortality. The relaunch of aprotinin was accompanied by a risk management to assess the pattern of use and safety of aprotinin in clinical practice. Data from centres enrolled in the Nordic Aprotinin Patient Registry are being collected and will be assessed in the final report.
The manuscript was reviewed by: P. Meybohm, Department of Anesthesiology, Intensive Care Medicine and Pain Therapy, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany; M.A.N.V.P. Morgado, CICS-UBI Health Sciences Research Centre, University of Beira Interior, Covilhã, Portugal; K. Zacharowski, Department of Anesthesiology, Intensive Care Medicine and Pain Therapy, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany. During the peer review process, Nordic Group, the marketing-authorization holder of aprotinin, was also offered an opportunity to provide a scientific accuracy review of their data. Changes resulting from comments received were made based on their scientific and editorial merit.
Compliance with ethical standards
The preparation of this review was not supported by any external funding.
Conflict of interest
K.A. Lyseng-Williamson is an employee of Adis International Ltd/Springer Nature and the Editor of Drugs & Therapy Perspectives, and has no other conflicts of interest to declare. The Editor of D&TP was not be involved in any publishing decisions for the manuscript.
- 1.Aprotinin 10,000 KIU/ml injection BP: UK summary of product characteristics. Reading: Nordic Pharma Limited; 2017.Google Scholar
- 2.Committee for Medicinal Products for Human Use (CHMP). Assessment report: antifibrinolytics containing aprotinin, aminocaproic acid and tranexamic acid. London: European Medicines Agency; 2013.Google Scholar
- 6.European Medicines Agency. European Medicines Agency recommends lifting suspension of aprotinin. Media release; 17 Feb 2012.Google Scholar
- 9.Michalets E, Harris L. Chapter 44. Antifibrolytics: pharmacologic profile and clinical utilization. In: Topaz, O, editor. Cardiovascular thrombus: from pathology and clinical presentations to imaging, pharmacotherapy and interventions. Cambridge (MA): Academic Press; 2018. p. 615–49.Google Scholar
- 15.Greilich PE, Okada K, Latham P, et al. Aprotinin but not ε-aminocaproic acid decreases interleukin-10 after cardiac surgery with extracorporeal circulation: randomized, double-blind, placebo-controlled study in patients receiving aprotinin and ε-aminocaproic acid. Circulation. 2001;104(Suppl 1):I265–9.CrossRefGoogle Scholar
- 29.Menichetti A, Tritapepe L, Ruvolo G, et al. Changes in coagulation patterns, blood loss and blood use after cardiopulmonary bypass: aprotinin vs tranexamic acid vs epsilon aminocaproic acid. J Cardiovasc Surg. 1996;37(4):401–7.Google Scholar
- 37.Meybohm P, Herrmann E, Nierhoff J, et al. Aprotinin may increase mortality in low and intermediate risk but not in high risk cardiac surgical patients compared to tranexamic acid and ε-aminocaproic acid: a meta-analysis of randomised and observational trials of over 30.000 patients. PLoS One. 2013;8(3):e58009.CrossRefGoogle Scholar
- 42.European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCEPP). Non-interventional post-authorisation safety study of pattern of use of Nordic Aprotinin: Nordic Aprotinin Patient Registry (EUPAS11384). http://www.encepp.eu/encepp/viewResource.htm?id=27958. Accessed 2019 Sep 30.